N/A Completed N=36 Randomized Single-blind Treatment

The Effect of Salmeterol on Eosinophil (EOS) Function

Source: ClinicalTrials.gov NCT00214019 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2016

Primary outcomePrimary: Sputum Eosinophils (EOS) 24 Hours Post Antigen Challenge — 3.5; 2.4; 0.54; 2.4 Eosinophil percentage

Summary

This study is designed to test the hypothesis that salmeterol use, and not fluticasone use or the combination treatment with fluticasone and salmeterol, is associated with a greater number of sputum eosinophils following antigen challenge and, under these circumstances, the migrating peripheral blood eosinophils are less adherent.

Outcome Measures

Outcome	Result	p-value
PRIMARY Sputum Eosinophils (EOS) 24 Hours Post Antigen Challenge	3.5; 2.4; 0.54; 2.4	—

Eligibility Criteria

Inclusion Criteria

18-55 years of age
history of asthma symptoms for the previous 6 months
Forced Expiratory Value (FEV1) >75% of predicted
positive prick skin test to cat, house dust mite or ragweed

Exclusion Criteria

history of life threatening asthma or anaphylaxis
current smoker
pregnant or breast-feeding
evidence of an upper respiratory infection within 4 weeks of screening

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00214019). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.